Anzeige
Mehr »
Login
Dienstag, 01.04.2025 Börsentäglich über 12.000 News von 695 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3EMJP | ISIN: US52187K2006 | Ticker-Symbol: 5MC
Tradegate
31.03.25
20:22 Uhr
0,304 Euro
+0,020
+7,04 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
LEAP THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
LEAP THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
0,2800,30031.03.
0,2680,30031.03.

Aktuelle News zur LEAP THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoH.C. Wainwright maintains neutral on Leap Therapeutics stock6
MiLEAP THERAPEUTICS, INC. - S-8, Securities to be offered to employees in employee benefit plans5
MiPenny Stock Leap Therapeutics Unveils Positive Data From Experimental Combo Therapy For Colorectal Cancer4
MiLeap Therapeutics, Inc.: Leap Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results238Leap to host a conference call to present updated CRC clinical data today, March 26, 2025, at 8:00 a.m. ET CAMBRIDGE, Mass., March 26, 2025 /PRNewswire/ --...
► Artikel lesen
LEAP THERAPEUTICS Aktie jetzt für 0€ handeln
MiLeap Therapeutics, Inc.: Leap Therapeutics Reports Positive Updated Data from Sirexatamab Colorectal Cancer Study222Updated data confirms statistically significant 32% higher ORR and 3.5 month longer PFS in second-line CRC patients with high DKK1 levels treated with sirexatamab...
► Artikel lesen
MiLeap Therapeutics GAAP EPS of -$0.37 misses by $0.014
MiLEAP THERAPEUTICS, INC. - 10-K, Annual Report-
MiLEAP THERAPEUTICS, INC. - 8-K, Current Report2
17.03.LEAP THERAPEUTICS, INC. - 8-K, Current Report3
29.01.Leap Therapeutics cut to Neutral at Baird after mid-stage trial setback9
29.01.Leap Therapeutics (NASDAQ:LPTX) Stock Rating Lowered by Robert W. Baird2
29.01.Leap Therapeutics (NASDAQ:LPTX) Downgraded by HC Wainwright to Neutral4
28.01.Leap Therapeutics Halts Sirexatamab Combo Therapy For Gastric Cancer ON Unclear Positive Signal, Stock Crashes4
28.01.Leap Therapeutics-Aktie stürzt ab nach Abbruch der DisTinGuish-Studie bei fortgeschrittenem Magenkrebs20
28.01.Leap Therapeutics stock plummets as it will discontinue DisTinGuish study in advanced gastric cancer3
28.01.LEAP THERAPEUTICS, INC. - 8-K, Current Report2
28.01.Leap Therapeutics, Inc.: Leap Therapeutics Reports Initial Clinical Data from Part B of the DeFianCe Study and Part C of the DisTinGuish Study13735% objective response rate (ORR) in second-line colorectal cancer (CRC) patients treated with sirexatamab (DKN-01) plus bevacizumab and chemotherapy, compared to...
► Artikel lesen
13.11.24Leap Therapeutics GAAP EPS of -$0.44 beats by $0.044
13.11.24Leap Therapeutics, Inc.: Leap Therapeutics Reports Third Quarter 2024 Financial Results149CAMBRIDGE, Mass., Nov. 13, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology...
► Artikel lesen
13.11.24LEAP THERAPEUTICS, INC. - 8-K, Current Report-
Seite:  Weiter >>
24 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1